0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
   THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. 
 
   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN 
WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, 
JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO 
DISTRIBUTE THIS ANNOUNCEMENT 
 
   PUBLICATION IN APPLICATION OF ARTICLE 15 OF THE BELGIAN TRANSPARENCY ACT 
OF 2 MAY 2007 
 
   Acacia Pharma Group plc 
 
   Admission to Trading on Euronext Brussels 
 
 
 
   Cambridge, UK and Indianapolis, US -- 23 February 2021, 08:00 CET: 
Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: 
ACPH), a commercial stage biopharmaceutical company focused on 
developing and commercializing novel products to improve the care of 
patients undergoing serious medical treatments such as surgery, invasive 
procedures, or chemotherapy, announces that, further to the 
announcements on 18 February 2021 and 19 February 2021 regarding a 
placing of new ordinary shares in the Company (the "New Ordinary 
Shares") by means of an accelerated bookbuild offering (the "Placing"), 
10,000,000 New Ordinary Shares have been issued and admitted to trading 
on the regulated market of Euronext Brussels. 
 
   The New Ordinary Shares issued pursuant to the Placing have the same 
rights and benefits as, and rank pari passu in all respects with, the 
existing Ordinary Shares. 
 
   Following issuance of the New Ordinary Shares, as per 23 February 2021, 
the Company's total issued share capital amounts to GBP1,993,789.02, 
represented by 99,689,451 ordinary shares with one voting right per 
share. The Company does not hold any ordinary shares in treasury and has 
not issued any other voting securities. Therefore, the total number of 
voting rights in the Company is 99,689,451. This number represents the 
denominator for purposes of notifications under transparency 
regulations. 
 
   On the basis of this information, shareholders of the Company can verify 
whether they are above or below one of the thresholds of 5%, 10%, 15%, 
20% and so on, in multiples of five, of the total voting rights, and 
whether there is therefore an obligation to disclose that they have 
reached, exceeded or fallen below any such threshold in accordance with 
the Belgian Transparency Act of 2 May 2007. Notifications of major 
shareholdings must be sent by email to Acacia Pharma, for the attention 
of Ali Elsley at AliElsley@acaciapharma.com, as well as to the Belgian 
Financial Services and Markets Authority (FSMA), at trp.fin@fsma.be. 
 
   The Company has in total 2,437,960 outstanding options and 2,861,500 
Restricted Stock Units, for the benefit of current and former staff and 
the managers of the group, conferring entitlement to subscribe for a 
maximum total of 5,299,460 new ordinary shares, each conferring one 
voting right. 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   Citigate Dewe Rogerson 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@citigatedewerogerson.com 
----------------------------------  -------------------------------------- 
 
  US Investors                        Media in Belgium and the Netherlands 
  LifeSci Advisors                    Chris Van Raemdonck 
  Irina Koffler                       +32 499 58 55 31 
  +1 917-734-7387                     chrisvanraemdonck@telenet.be 
  ikoffler@lifesciadvisors.com 
----------------------------------  -------------------------------------- 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
marketed in the US for the management of postoperative nausea & vomiting 
(PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centered in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   www.acaciapharma.com 
 
   Important Information 
 
   These materials are not for release, publication or distribution, 
directly or indirectly, in whole or in part, into or within the United 
States (including its territories and possessions, any State of the 
United States and the District of Columbia). These materials are for 
informational purposes only and do not constitute or form part of any 
offer or solicitation to purchase or subscribe for securities in the 
United States. The securities referred to herein have not been and will 
not be registered under the United States Securities Act of 1933, as 
amended (the "US Securities Act"), or under the securities laws of any 
state or other jurisdiction of the United States. The securities 
referred to herein may not be offered or sold in the United States 
except pursuant to an exemption from the registration requirements of 
the US Securities Act and in compliance with any applicable securities 
laws of any state or other jurisdiction of the United States. There will 
be no public offer of securities in the United States. 
 
   This press release (and the information contained herein) is not for 
release, publication or distribution, directly or indirectly, in whole 
or in part, into or within Australia, Canada, Japan or South Africa or 
any other jurisdiction where to do so might constitute a violation of 
the relevant laws or regulations of such jurisdiction. 
 
   The offer set out in this press release is only addressed to and is only 
directed at persons in member states of the European Economic Area (the 
"EEA") who are "qualified investors" within the meaning of Article 2 (e) 
of Regulation (EU) 2017/1129. In the United Kingdom, this press release 
is addressed solely to, and is directed solely at, persons who (i) have 
professional experience in matters relating to investments falling 
within Article 19(5) of the Financial Services and Markets Act 2000 
(Financial Promotion) Order 2005 (the "Order") or (ii) are persons 
falling within Article 49(2)(a) to (e) of the Order and other persons to 
whom it may lawfully be communicated (all such persons together being 
referred to as "relevant persons"). These materials are addressed only 
to, and directed only at, relevant persons and qualified investors and 
must not be acted on or relied on (i) in the United Kingdom, by persons 
who are not relevant persons or (ii) in any member state of the EEA, by 
persons who are not qualified investors. Any investment or investment 
activity to which these materials relate is available only to, and any 
invitation, offer or agreement to subscribe, purchase or otherwise 
acquire any securities referred to herein will be engaged in only with, 
in the United Kingdom, relevant persons, and in any member state of the 
EEA, qualified investors. 
 
   This press release does not constitute, or form part of, any offer or 
any solicitation of an offer to subscribe for any shares or other 
securities. 
 
 
 
 

(END) Dow Jones Newswires

February 23, 2021 02:00 ET (07:00 GMT)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024